Maccura Biotechnology Co.Ltd

300463

CNE1000020H3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
11.77 ^CNY	-1.26%		-5.54%	-21.90%

Apr. 01	Tranche Update on Maccura Biotechnology Co.Ltd's Equity Buyback Plan announced on February 6, 2024.	CI
Feb. 05	Maccura Biotechnology Co.Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	CI

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2021

April 20, 2022 at 03:34 pm EDT

Maccura Biotechnology Co.Ltd proposed final cash dividend of CNY 4.68000000 per 10 shares (tax included) for the year 2021.

Latest news about Maccura Biotechnology Co.Ltd

Tranche Update on Maccura Biotechnology Co.Ltd's Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Maccura Biotechnology Co.Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	Feb. 05	CI
Maccura Biotechnology Co.Ltd authorizes a Buyback Plan.	Feb. 04	CI
Maccura Biotechnology Co.Ltd(SZSE:300463) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Maccura Biotechnology Co.Ltd(SZSE:300463) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Maccura Biotechnology Registers Infectious Disease Diagnosis Kit	23-08-04	MT
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-28	CI
Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2022, Payable on May 29, 2023	23-05-16	CI
Maccura Biotechnology Co.Ltd Proposes Final Cash Dividend for 2022	23-04-25	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-15	CI
Mega Genomics Braves Market Turbulence, Raises $19.5 Million in Hong Kong IPO	22-06-20	MT
Mega Genomics Braves Market Turbulence with Launch of $34 Million Hong Kong IPO	22-06-10	MT
DMaccura Biotechnology Co.Ltd Approves Cash Dividend for 2021, Payable on May 19, 2022	22-05-13	CI
Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2021	22-05-11	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2021	22-04-20	CI
Maccura Biotechnology Co.Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-19	CI
Maccura Biotechnology Nets $246 Million From Private Placement	22-02-17	MT
Maccura Biotechnology Co.Ltd announced that it has received CNY 1.57416 billion in funding from a group of investors	22-01-24	CI
Maccura Biotechnology Co.Ltd Announces Board Appointments	22-01-18	CI
Beijing Guoke Biotechnology Co., Ltd. announced that it has received $3.14 million in funding from Maccura Biotechnology Co.Ltd, Chengdu Huiling Changxi Fund	21-11-29	CI

Chart Maccura Biotechnology Co.Ltd

Duration

Period

More charts

Maccura Biotechnology Co., Ltd., formerly Sichuan Maccura Biotechnology Co., Ltd., is a China-based company principally engaged in research, development, manufacture and sales of in-vitro diagnostics products and the sales of in-vitro diagnostic products of foreign brands as an agent. The Company provides hundreds of products which cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-24 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Maccura Biotechnology Co.Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.66

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
MACCURA BIOTECHNOLOGY CO.LTD	-21.90%	996M
BIOMÉRIEUX	-1.04%	12.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.62%	6.99B
DIASORIN S.P.A.	-2.21%	5.1B
LANTHEUS HOLDINGS, INC.	+1.76%	4.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-4.79%	4.27B
10X GENOMICS, INC.	-49.07%	3.45B
ANDON HEALTH CO., LTD.	+7.09%	2.61B
VITROLIFE AB	-15.92%	2.08B
MYRIAD GENETICS, INC.	-2.80%	1.67B

Diagnostic & Testing Substances